For breakthrough cancer pain when morphine fails

Prescrire International

Volumn 11, Issue 60, 2002, Pages 106-107

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL CITRATE; MORPHINE; OPIATE AGONIST; FENTANYL; NARCOTIC ANALGESIC AGENT;

ANALGESIA; ARTICLE; CANCER PAIN; CANCER PATIENT; CLINICAL TRIAL; CONFUSION; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG EFFICACY; DRUG INDICATION; DRUG PACKAGING; DRUG RELEASE; FRANCE; HALLUCINATION; HUMAN; NAUSEA AND VOMITING; RISK ASSESSMENT; SUSTAINED RELEASE FORMULATION; TREATMENT FAILURE; VERTIGO; ADULT; BUCCAL DRUG ADMINISTRATION; CHILD; CONTROLLED CLINICAL TRIAL; DRUG DOSAGE FORM; MOUTH MUCOSA; NEOPLASM; ORAL DRUG ADMINISTRATION; PAIN; RANDOMIZED CONTROLLED TRIAL; SAFETY; TREATMENT OUTCOME;

ADMINISTRATION, BUCCAL; ADMINISTRATION, ORAL; ADULT; ANALGESICS, OPIOID; CHILD; DOSAGE FORMS; FENTANYL; FRANCE; HUMANS; MORPHINE; MOUTH MUCOSA; NEOPLASMS; PAIN; RANDOMIZED CONTROLLED TRIALS; SAFETY; TREATMENT OUTCOME;

EID: 0036675927     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Prescrire Editorial Staff "Improving care of terminally ill patients" Prescr Int 1997; 6 (32): 179-184.
2. Prescrire Rédaction "morphine-Moscontino LP 200 mg" Rev Prescr 1996; 16 (162): 369-370 + (164): 580.
3. Prescrire Rédaction "Skenan LPo 200 mg" Rev Prescr 1997; 17 (174): 417.
4. Prescrire Rédaction "Kapanol LPo" Rev Prescr 1998; 18 (187): 566-568 + (189): 799.
5. "Fentanyl". In: "Martindale The Complete Drug Reference" 32nd ed, The Pharmaceutical Press. London 1999: 38-41.
6. Prescrire Editorial Staff "Transdermal fentanyl patch" Prescr Int 1998; 7 (37): 138-140.
7. Patt RB and Ellison NM "Breakthrough pain in cancer patients: characteristics, prevalence, and treatment" Oncology 1998; 12 (7): 1035-1046 + 1049-1052.
8. Expert working group on the research network of the European association for palliative care "Morphine and alternative opioids in cancer pain: the EAPC recommendations" Br J Cancer 2001; 84 (5): 587-593.
9. Cleary JF "Pharmacokinetic and pharmacodynamic issues in the treatment of breakthrough pain" Semin Oncol 1997; 24 (5 suppl. 16): 13-19.
10. Stevens RA and Ghazi SM "Routes of opioid analgesic therapy in the management of cancer pain" Cancer Control 2000; 7 (2): 132-141.
11. Agence française de sécurité sanitaire des produits de santé "Résumé des caracitéristiques du produit Actiqo" 11 June 2001; 10 pages.
12. "Actiqo". In: "The Physicians' Desk Reference" Medical Economics Company, Montvale 2001: 556-560.
13. Lichtor JL et al. "The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain" Anesthesia Analgesia 1999; 89 (3): 732-738.
14. Portenoy RK et al. "Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study" Pain 1999; 79: 303-312.
15. Christie JM et al. "Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain" J Clin Oncol 1998; 16 (10): 3238-3245.
16. Coluzzi PH et al. "Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFCo) and morphine sulfate immediate release (MSIR)" Pain 2001; 91: 123-130.
17. Food and Drug Administration - Center for Drug Evaluation and Research "Actiqo-medical review" 10 October 1997; 38 pages.
18. "Actiqo". In: "British National Formulary" British Medical Association - Royal Pharmaceutical Society of Great Britain, London September 2001; (42): 216.
19. Farrar JT et al. "Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients" J Natl Cancer Inst 1998; 90 (8): 611-616.